Top Page
SkinBioTherapeutics
(LSE:SBTX)
SkinBioTherapeutics (SBTX) vs. iShares MSCI United Kingdom ETF (EWC)
SkinBioTherapeutics Business Overview & Revenue Model
SkinBioTherapeutics Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.64M | 1.21M | 132.06K | 74.76K | 0.00 |
| Gross Profit | 2.71M | 683.04K | 85.19K | 45.34K | -5.05K |
| EBITDA | -196.54K | -2.72M | -2.96M | -2.95M | -1.49M |
| Net Income | -696.25K | -2.88M | -2.84M | -2.79M | -1.43M |
Balance Sheet | |||||
| Total Assets | 12.13M | 5.22M | 2.59M | 3.08M | 5.73M |
| Cash, Cash Equivalents and Short-Term Investments | 4.78M | 800.90K | 1.31M | 1.80M | 4.61M |
| Total Debt | 993.47K | 818.74K | 100.65K | 127.86K | 139.85K |
| Total Liabilities | 2.71M | 2.25M | 599.34K | 609.61K | 519.67K |
| Stockholders Equity | 9.42M | 2.97M | 1.99M | 2.48M | 5.22M |
Cash Flow | |||||
| Free Cash Flow | -1.30M | -2.92M | -2.81M | -2.77M | -1.67M |
| Operating Cash Flow | -1.30M | -2.73M | -2.65M | -2.67M | -1.56M |
| Investing Cash Flow | -1.62M | -2.30M | -165.28K | -96.81K | -112.31K |
| Financing Cash Flow | 6.90M | 4.51M | 2.32M | -35.12K | 4.12M |
SkinBioTherapeutics Technical Analysis
SkinBioTherapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £27.18M | -1.64 | -204.29% | ― | 3.31% | 21.91% | |
52 Neutral | £22.92M | -3.03 | -213.66% | ― | 39.88% | 81.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | £31.57M | -3.00 | -259.88% | ― | ― | ― | |
43 Neutral | £30.45M | -54.98 | -10.01% | ― | 283.74% | 78.57% | |
43 Neutral | £5.94M | -2.61 | -2.42% | ― | ― | ― | |
37 Underperform | £53.13M | -2.25 | -506.43% | ― | 63.25% | 8.94% |
SkinBioTherapeutics Corporate Events
SkinBioTherapeutics, a UK AIM-listed life science group specialising in skin health technologies and microbiome-based products, develops cosmetic skincare through its SkinBiotix platform and gut-skin axis supplements under the AxisBiotix brand. The company works with Croda on the Zenakine active ingredient and is expanding its footprint via acquisitions that add new distribution channels and manufacturing capacity.
The group has appointed beauty and wellness veteran Rachel Parsonage as interim CEO for six months, with a concurrent Board role pending standard regulatory checks. Executive chairman Martin Hunt said her turnaround and stakeholder-management experience is central to efforts to stabilise the business, support a forensic investigation into current issues and refocus SkinBioTherapeutics on restoring momentum and accelerating growth.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £7.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
SkinBioTherapeutics, which also pursues acquisitions in complementary skincare and cosmetic fields to expand distribution, geography and manufacturing, has been listed on AIM since 2017 and operates from Newcastle. The group aims to leverage its platform technologies across multiple skin health pillars while using consolidation to broaden routes to market for its in-house products.
The company has appointed new Non-Executive Director and Audit Committee Chair Alyson Levett to oversee an ongoing investigation process on behalf of the board. It has also engaged FRP Advisory to conduct an independent forensic review into previously outlined matters, aiming to expedite completion so that interim results can be issued with confidence and management can refocus on running and growing the business, with further updates to follow as appropriate.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £6.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
SkinBioTherapeutics has uncovered potential misrepresentation by its former CEO that casts serious doubt on £0.77m of accrued royalty income booked in its FY25 audited accounts, and now expects to remove this income, cutting FY25 revenue to £3.87m and widening adjusted EBITDA losses to £1.17m. While the board stresses that key contracts, core businesses Dermatonics and Bio-Tech Solutions, and AxisBiotix™ sales remain sound and cash stood at £2.92m on 13 February 2026, it has launched a broader review of financial reporting, warned that FY26 results will fall significantly below market expectations, and is moving to appoint an interim and then permanent CEO as the chairman temporarily assumes executive control.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
SkinBioTherapeutics plc, a life science company specialising in skin health technologies and products, develops cosmetic skincare actives through its SkinBiotix® platform and gut-skin axis food supplements under the AxisBiotix™ brand, supported by retail and e-commerce distribution. Through partnerships, including with Croda for Zenakine™, and acquisitions that add manufacturing and geographic reach, the company is building a vertically integrated skin healthcare portfolio from its Newcastle base.
The company announced that CEO Stuart Ashman has resigned following his suspension pending an investigation into matters related to his conduct, with a full inquiry underway supported by external professional advisers. Non-Executive Chairman Martin Hunt has stepped in as Executive Chairman on an interim basis while the board launches a search for both an interim and a permanent chief executive, a leadership transition that introduces near-term uncertainty but is designed to maintain operational continuity and reassure markets and shareholders about governance standards.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £19.50 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
SkinBioTherapeutics has issued 259,472 new ordinary shares following the exercise of share options granted to a former employee at the time of its IPO, with admission of the new stock to trading on AIM scheduled for 13 February 2026. The enlarged share capital will comprise 259,168,671 ordinary shares, a new total that will be used by investors to calculate disclosure thresholds for changes in significant holdings under UK transparency rules.
The share issuance marginally dilutes existing shareholders but reflects the crystallisation of long-standing incentive arrangements dating back to the company’s market listing. By clarifying the updated voting rights and share count, the company provides greater visibility for market participants monitoring ownership positions and regulatory reporting obligations.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £19.50 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
SkinBioTherapeutics plc, a UK-listed life science company specialising in skin health technologies and consumer products, has increased its total number of ordinary shares in issue to 258,909,199 following the admission of 129,736 new shares arising from the exercise of share options. The updated share capital figure will serve as the new denominator for investors assessing whether they must disclose holdings or changes in their ownership under UK regulatory transparency rules, providing clarity for shareholders and ensuring ongoing compliance with market disclosure requirements.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £18.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
SkinBioTherapeutics has issued 129,736 new ordinary shares following the exercise of share options granted to a former employee at the time of its IPO, with admission of the new stock to trading on AIM scheduled for 22 January 2026. Following this modest equity issuance, the company’s total shares in issue will rise to 258,779,463, a change that slightly increases its equity base and voting rights denominator for shareholders under FCA disclosure rules but does not materially alter its operational strategy or market positioning in the skin health sector.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £21.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
SkinBioTherapeutics has strengthened its senior leadership team with the appointment of experienced non-executive director and audit specialist Alyson Levett as a non-executive director and Chair of the Audit Committee, and the promotion of Group Finance Director Emily Bertram to Chief Financial Officer and executive board member, effective 1 January 2026. The board reshuffle, which also sees former director Danielle Bekker step down from the board to remain as an external advisor, is positioned by the company as enhancing financial oversight and governance support at a time when management expects an especially active year ahead, potentially improving investor confidence and operational execution as it pursues its growth and consolidation strategy in the skin health sector.
The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
SkinBioTherapeutics reported that all resolutions at its Annual General Meeting were passed, including the receipt of accounts, reappointment and fee-setting authority for its auditor, and broad authorities for directors to allot shares and equity securities, including on a non-pre-emptive basis and in connection with acquisitions or other capital investments. The voting outcomes, which showed strong but not unanimous support across all items, confirm shareholder backing for the company’s current governance, financing flexibility and acquisition-led growth strategy as it continues to develop and commercialise its skin health technologies across cosmetic and supplement markets.
The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
SkinBioTherapeutics plc announced that its trading has begun positively for the new financial year, reaffirming that its 2026 full-year revenue and adjusted EBITDA projections remain on target at £6.2 million and £0.7 million, respectively. This positive outlook reflects the company’s ongoing efforts to solidify its market position in the skincare and gut-skin health sectors, which is bolstered by its partnerships, innovative product lines, and strategic expansion initiatives.
The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
SkinBioTherapeutics plc has announced the posting of its Annual Report and Accounts for the year ending 30 June 2025, alongside the Notice of its Annual General Meeting (AGM) scheduled for 29 December 2025. The company continues to strengthen its position in the skin health industry through strategic partnerships and acquisitions, aiming to enhance its market presence and operational capabilities. This announcement underscores its commitment to transparency and growth, potentially impacting stakeholders positively by expanding its product reach and technological applications.
The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.